Active Pharmaceutical Ingredients Market - The Position of the Major Leaders After FIVE Years

1
MarketsandMarkets Presents
Active Pharmaceutical Ingredients Market The
Position of the Major Leaders After FIVE Years
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
2
The report "Active Pharmaceutical
Ingredients/API Market by Type (Innovative,
Generic), Manufacturer (Captive, Merchant),
Synthesis (Synthetic, Biotech), Product (mAb,
Hormone) Drug (OTC, Rx), Therapy (Diabetes,
Oncology, CNS, CVD) - Global Forecast to 2021",
analyzes and studies the major market drivers,
restraints, opportunities, and challenges in
North America, Europe, Asia, and the Rest of the
World (RoW). Browse 369 market data tables 46
figures 312 pages And in-depth TOC on Active
Pharmaceutical Ingredients/API Market Download
The PDF Brochure_at_ https//www.marketsandmarkets.co
m/pdfdownload.asp?id263 The global active
pharmaceutical ingredients market is expected to
reach USD 213.97 Billion by 2021 from USD 157.95
Billion in 2016, growing at a CAGR of 6.3 from
2016 to 2021.
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
3

• Market Stakeholders
• Medical image management software providers
• Diagnostic imaging equipment vendors/service
  providers
• Standalone image management software/workstation
  providers
• Healthcare IT service providers
• Research and consulting firms
• Diagnostic imaging centers
• Hospitals
• Venture capitalists
• Government agencies
• Market research and consulting firms

https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
4

• Market Drivers
• Increasing Incidence of Chronic Diseases
• Rising Prevalence of Cancer
• Technological Advancements in API Manufacturing
• Growing Importance of Generics
• Rapidly Increasing Geriatric Population
• Increase in Abbreviated New Drug Applications
  (ANDA)
• Increasing Uptake of Biopharmaceuticals
• Talk to Our Research Experts_at_ https//www.markets
  andmarkets.com/speaktoanalyst.asp?id263
• Restraints
• Stringent Regulatory Requirements
• Unfavorable Drug Price Control Policies Across
  Various Countries

https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
5
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
6
On the basis of type, the active pharmaceutical
ingredients market is segmented into innovative
and generic APIs. The innovative APIs segment is
estimated to command the largest share in 2016.
Some of the major factors contributing to its
large share include growing demand for innovative
therapeutics for treatment of dreadful diseases,
especially cancer, the increase in the number of
FDA approvals for new molecular entities and the
higher prices of innovative APIs (as compared to
generics). On the basis of type of manufacturer,
the active pharmaceutical ingredients market is
segmented into captive and merchant API
manufacturers. The APIs market, on the basis of
type of synthesis, is segmented into synthetic
and biotech APIs. Synthetic APIs is estimated to
dominate this market in 2016.
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
7
The large share of this segment can be attributed
to the emergence of new synthetic molecules in
the market, increasing number of new product
approvals, less complex manufacturing and
approval processes as compared to biologics and
technological advancements in the method of
synthesis. However, the biotech APIs market is
expected to grow at a substantially higher rate
during the forecast period owing to advances in
biotechnology, growing demand for
biopharmaceuticals due to their specificity in
action, their similarity with the natural
biological compounds, and significant growth in
the demand for monoclonal antibodies. Based on
product, the biotech active pharmaceutical
ingredients market is segmented into monoclonal
antibodies, hormones, vaccines, cytokines, fusion
proteins, therapeutic enzymes, and blood factors.
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
8
In 2015, the monoclonal antibodies segment
account accounted for the largest share of the
global biotech active pharmaceutical ingredients
market. Growing incidence of cancer, increasing
investments in RD, technological advances in
genetic sequencing and target gene selection, and
increasing application of mAbs in oncology
reduced side effects as compared to chemotherapy
are some of the major factors responsible for the
large share of monoclonal antibodies in this
market. Based on geography, the global active
pharmaceutical ingredients market is segmented
into North America, Europe, Asia, and the Rest of
the World (RoW). North America is expected to
account for the largest share of the market by
the end of 2016. This large share can be
attributed to various factors including
increasing incidence of chronic diseases,
increasing focus of the government on the growing
adoption of generic drugs, rising demand for
biologics and specialty drugs, and technological
advances in API manufacturing.
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
9

• Prominent Players
• Pfizer, Inc. (U.S.)
• Novartis International AG (Switzerland)
• Sanofi (France)
• Boehringer Ingelheim (Germany)
• Bristol-Myers Squibb (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Eli Lilly and Company (U.S.)
• GlaxoSmithKline plc (U.K.)
• Merck Co., Inc. (U.S.)
• AbbVie Inc. (U.S.).

https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
10
The Active pharmaceutical ingredients market is
highly competitive and fragmented with many big
and small players as well as contract
manufacturing organizations. Pfizer, Inc., a
leading player in the APIs market. Pfizers
leading position in the market can be attributed
to its exhaustive product portfolio spread across
its business segments includng Global Innovative
Pharmaceuticals (GIP) Global Established
Pharmaceuticals (GEP) and Global Vaccines,
Oncology. As part of its growth strategy, the
company focuses on adopting both organic and
inorganic growth strategies such as agreements,
partnerships, collaborations, approvals, and
acquisitions. In accordance with this, in June
2016, Pfizer acquired Anacor Pharmaceuticals,
Inc. (U.S.), a leading biopharmaceutical company
developing small molecule therapeutics.
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
11
Novartis International AG (Switzerland), is
another leading player in this market. The
companys strengths lie in its strong brand
recognition and robust product portfolio. the
company invests a significant amount of its
revenue in RD activities. In 2015, the company
invested 18.0 of its total revenue (USD 8.9
billion) on RD. This significant investment in
RD enables the company to launch innovative and
technologically advanced products in the market.
Novartis also focuses on inorganic growth
strategies to sustain its foothold in the market.
For instance, in June 2016, Novartis entered into
a licensing and collaboration agreement with
Xencor (U.S.), a biopharmaceutical company that
develops engineered monoclonal antibodies. The
purpose of this agreement was to develop
bispecific antibodies for treating cancer.
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
12
The key strategies followed by most companies in
the Active pharmaceutical ingredients market are
agreements, collaborations, partnerships, joint
ventures, and alliances regulatory approvals,
mergers and acquisitions expansions and
investments. Among all growth strategies adopted
by market players, agreements, collaborations,
partnerships, joint ventures, and alliances
accounted for the largest share of the overall
growth strategies mapped from 2013 to 2016.
Some leading players adopting these strategies
include Pfizer, Inc. (U.S.), Novartis
International AG (Switzerland), Sanofi (France),
Boehringer Ingelheim (Germany), Teva
Pharmaceutical Industries Ltd. (Israel), and
Merck Co., Inc. (U.S.).
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
13
About MarketsandMarkets MarketsandMarkets
provides quantified B2B research on 30,000 high
growth niche opportunities/threats which will
impact 70 to 80 of worldwide companies
revenues. Currently servicing 5000 customers
worldwide including 80 of global Fortune 1000
companies as clients. Almost 75,000 top officers
across eight industries worldwide approach
MarketsandMarkets for their painpoints around
revenues decisions. Our 850 fulltime analyst and
SMEs at MarketsandMarkets are tracking global
high growth markets following the "Growth
Engagement Model GEM". The GEM aims at
proactive collaboration with the clients to
identify new opportunities, identify most
important customers, write "Attack, avoid and
defend" strategies, identify sources of
incremental revenues for both the company and its
competitors. MarketsandMarkets now coming up
with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies,
innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets is
determined to benefit more than 10,000 companies
this year for their revenue planning and help
them take their innovations/disruptions early to
the market by providing them research ahead of
the curve. MarketsandMarketss flagship
competitive intelligence and market research
platform, "Knowledgestore" connects over 200,000
markets and entire value chains for deeper
understanding of the unmet insights along with
market sizing and forecasts of niche markets.   
https//www.marketsandmarkets.com/Market-Reports/A
PI-Market-263.html
14
Contact Us
Mr. Shelly Singh MarketsandMarkets INC. 630
Dundee Road Suite 430 Northbrook, IL 60062 USA
1-888-600-6441 Email sales_at_marketsandmarkets.c
om MarketsandMarkets Bloghttp//www.marketsandma
rkets.comhttp//twitter.com/marketsmarkets http/
/www.linkedin.com/company/marketsandmarkets
15
(No Transcript)